StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-26 | $153.12 | $154.89 | +1.16% | 2.4M |
| 05-27 | $153.69 | $153.00 | -0.45% | 2.9M |
| 05-28 | $153.47 | $154.63 | +0.76% | 2.7M |
| 05-29 | $155.66 | $157.48 | +1.17% | 6.7M |
| 06-01 | $159.95 | $163.68 | +2.33% | 6.7M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-1.18B | $-689.52M | $-473.21M | $-297.50M |
Net Income | $-1.13B | $-600.09M | $-405.52M | $-133.23M |
EPS (Diluted) | $-5.95 | $-3.58 | $-2.45 | $-1.51 |
Total Assets | $2.35B | $2.56B | $1.76B | $1.81B |
Total Liabilities | $723.21M | $293.10M | $196.69M | $189.59M |
Cash & Equivalents | $383.75M | $543.06M | $201.26M | $275.71M |
Free Cash Flow OCF − CapEx | $-913.73M | $-567.74M | $-428.23M | $-294.29M |
Shares Outstanding | 197.00M | 185.90M | 167.75M | 165.65M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
No sell-side coverage available for RVMD yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.